The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and ...

A more potent GLP-1 drug, it has shown superior results to Jardiance in cutting heart attacks ... Saxenda (Victoza under a different dose and brand name), which Maziar Mike Doustdar says is ...

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart ...

Getting to know what’s going on in your body can help you manage type 2 diabetes well. It’s a chronic condition in which your body doesn’t use insulin properly. This causes sugar to build up ...